Increasing evidence has demonstrated that GLP-1R agonists exhibit a favorable benefit/risk profile and reduce the risk of myocardial infarction, stroke, cognitive disorder, and cardiovascular death [50,51]. This evidence concerns the gene GLP1R and Stroke.